ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 173 filers reported holding ENANTA PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $497,076 | -79.6% | 44,501 | -60.9% | 0.00% | -100.0% |
| Q2 2023 | $2,437,996 | -48.4% | 113,925 | -2.5% | 0.00% | -50.0% |
| Q1 2023 | $4,724,160 | -14.1% | 116,819 | -1.2% | 0.00% | 0.0% |
| Q4 2022 | $5,502,000 | -12.8% | 118,290 | -2.7% | 0.00% | 0.0% |
| Q3 2022 | $6,307,000 | +37.7% | 121,585 | +25.5% | 0.00% | 0.0% |
| Q2 2022 | $4,579,000 | -36.9% | 96,873 | -5.0% | 0.00% | 0.0% |
| Q1 2022 | $7,262,000 | -4.2% | 102,014 | +0.6% | 0.00% | 0.0% |
| Q4 2021 | $7,584,000 | +31.8% | 101,422 | +0.2% | 0.00% | 0.0% |
| Q3 2021 | $5,753,000 | +26.2% | 101,268 | -2.3% | 0.00% | +100.0% |
| Q2 2021 | $4,560,000 | -15.0% | 103,625 | -4.8% | 0.00% | -50.0% |
| Q1 2021 | $5,366,000 | +14.8% | 108,801 | -2.0% | 0.00% | 0.0% |
| Q4 2020 | $4,673,000 | -83.2% | 110,992 | -81.7% | 0.00% | -81.8% |
| Q3 2020 | $27,815,000 | -0.8% | 607,566 | +8.8% | 0.01% | -8.3% |
| Q2 2020 | $28,042,000 | +161.8% | 558,506 | +168.1% | 0.01% | +100.0% |
| Q1 2020 | $10,713,000 | +64.7% | 208,288 | +97.8% | 0.01% | +100.0% |
| Q4 2019 | $6,504,000 | +0.2% | 105,283 | -2.5% | 0.00% | 0.0% |
| Q3 2019 | $6,488,000 | -86.7% | 107,993 | -81.3% | 0.00% | -86.4% |
| Q2 2019 | $48,800,000 | +0.1% | 578,330 | +13.3% | 0.02% | 0.0% |
| Q1 2019 | $48,744,000 | +172.6% | 510,308 | +102.1% | 0.02% | +144.4% |
| Q4 2018 | $17,881,000 | -6.5% | 252,468 | +12.9% | 0.01% | +28.6% |
| Q3 2018 | $19,117,000 | +11.8% | 223,678 | +51.6% | 0.01% | -12.5% |
| Q2 2018 | $17,106,000 | +45.8% | 147,586 | +1.8% | 0.01% | +60.0% |
| Q1 2018 | $11,734,000 | +30.6% | 145,026 | -5.3% | 0.01% | +25.0% |
| Q4 2017 | $8,983,000 | +33.5% | 153,073 | +6.4% | 0.00% | +33.3% |
| Q3 2017 | $6,730,000 | +60.6% | 143,817 | +23.5% | 0.00% | +50.0% |
| Q2 2017 | $4,190,000 | +16.8% | 116,475 | +0.1% | 0.00% | 0.0% |
| Q1 2017 | $3,586,000 | -5.7% | 116,415 | +2.5% | 0.00% | 0.0% |
| Q4 2016 | $3,803,000 | +32.4% | 113,535 | +5.2% | 0.00% | 0.0% |
| Q3 2016 | $2,873,000 | +26.7% | 107,965 | +5.0% | 0.00% | +100.0% |
| Q2 2016 | $2,267,000 | +26.2% | 102,795 | +68.1% | 0.00% | 0.0% |
| Q1 2016 | $1,796,000 | -8.4% | 61,145 | +3.0% | 0.00% | 0.0% |
| Q4 2015 | $1,961,000 | -11.4% | 59,389 | -3.1% | 0.00% | 0.0% |
| Q3 2015 | $2,214,000 | +75.9% | 61,289 | +147.6% | 0.00% | 0.0% |
| Q4 2014 | $1,259,000 | +13.1% | 24,756 | -12.0% | 0.00% | 0.0% |
| Q3 2014 | $1,113,000 | -19.9% | 28,136 | -12.7% | 0.00% | 0.0% |
| Q2 2014 | $1,389,000 | +14.4% | 32,247 | +6.2% | 0.00% | 0.0% |
| Q1 2014 | $1,214,000 | +43.5% | 30,352 | -2.1% | 0.00% | 0.0% |
| Q4 2013 | $846,000 | +4.6% | 31,009 | -12.2% | 0.00% | 0.0% |
| Q3 2013 | $809,000 | +20125.0% | 35,317 | +15458.1% | 0.00% | – |
| Q2 2013 | $4,000 | – | 227 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 476,042 | $45,472,000 | 12.29% |
| Stonepine Capital Management, LLC | 60,840 | $5,811,000 | 3.34% |
| ACUTA CAPITAL PARTNERS, LLC | 61,000 | $5,827,000 | 2.77% |
| Virtus ETF Advisers LLC | 10,634 | $1,016,000 | 2.16% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 61,000 | $5,827,000 | 2.15% |
| ARMISTICE CAPITAL, LLC | 372,000 | $35,533,000 | 1.94% |
| Matarin Capital Management, LLC | 209,403 | $20,002,000 | 1.46% |
| Monashee Investment Management LLC | 50,000 | $4,776,000 | 1.10% |
| Granahan Investment Management | 151,322 | $14,454,000 | 0.78% |
| ALGERT GLOBAL LLC | 13,186 | $1,260,000 | 0.72% |